Clinical Trials of Recombinant Factor VIII
Preparations of plasma coagulation factors have been mainstays in the treatment of hemorrhagic disorders since their introduction in the middle 19th century. One of the first recorded uses of blood products to correct the hemorrhagic tendency in a hemophiliac was by Lane in 18401. By the middle of the present century, the use of whole plasma2 or various fractions derived from plasma3 was accepted therapy in hemorrhagic disorders although the large volumes required and the lack of plasma availability limited the use of these materials to major bleeding episodes. The development in 1964 of cryoprecipitate4, a cold-precipitated plasma fraction enriched in factor VIII, was a significant advance for patients with hemophilia. Not only was this used in the treatment of hemophilia for the next twenty years, but it was to be the starting material for many of the factor VIII concentrates to follow. In 1968, glycine-precipitated preparations of human factor VIII were first introduced for clinical use5. This procedure was amenable to large scale production of factor VIII and therefore to commercial preparation of factor VIII concentrates. By the early 1970s, factor VIII prepared in this way had become the major method for treatment of patients with hemophilia.
KeywordsFactor VIII Club Foot Domain Repeat Recombinant Factor VIII Human Factor VIII
Unable to display preview. Download preview PDF.
- 2.Feissly R. Etudes sur l’hemophilie. Bull Mem Soc Mod Hop Paris 1923; 47: 1778.Google Scholar
- 6.Horowitz B, Piet MPJ. Transmission of viral disease by plasma protein fractions. Plasma Ther Transfus Technol 1986; 7: 503–513.Google Scholar
- 8.Prince AM, Horowitz B, Brotman B. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet 1896; 1: 706–710.Google Scholar
- 9.Schimpf K, Brackmann HH, Kreuz W, Kraus B, Haschke F, Schramm W, Moesseler J, Auerswald G, Sutor AH, Keohler K, Hellstern P, Muntean W, Scharrer I. Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand’s disease with pasteurized factor VIII concentrate. New Eng J Med 1989; 321: 1148–1152.PubMedCrossRefGoogle Scholar
- 13.Truett MA, Blacher R, Burke RL, Caput D, Chu C, Dina D, Hartog K, Kuo CH, Masiarz FR, Merryweather JP, Najarian JR, Paschl C, Potter SJ, Pumma J, Quiroga M, Rail LB, Randolph A, Urdea M, Valenzuela P, Dahl HH, Favaloro J, Hansen J, Nordfang O, Ezban M. Characterization of the polypeptide composition of human factor VIII: C and the nucleotide sequence and expression of the human cDNA. DNA 1986; 4: 333–349.CrossRefGoogle Scholar
- 21.Pittman DD, Marquette KA, Kaufman RJ. Expression and characterization of factor VIII and factor V hybrid molecules produced in mammalian cells. Thrombos Haemostas 1989; 62: 34 (abstract).Google Scholar
- 25.Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine. Thrombos Haemostas 1989; 62: 34 (abstract).Google Scholar
- 27.van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor Villa in the activation of bovine factor X. J Biol Chem 1987; 256: 3433–3442.Google Scholar
- 34.Kaufman RJ. High level expression of proteins in mammalian cells. In: Setlow JK ed. Genetic Engineering. Principles and Methods. Volume 9. New York: Plenum Press, 1987: 155–198.Google Scholar
- 35.Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 1989; ss9: 1233–1242.Google Scholar
- 36.White GC II, McMillan CW, Gomperts E, Addiego J Jr, Brackmann H, Brettler D, Gill J, Goldsmith J, Hoots K, Kessler C, Kisker T, Laurian Y, Lewis B, Lusher J, Mannucci P, Morfini M, Scharrer I, Schulman S, Lee M, Courter S, Kingdon H, Roberts H. Safety and efficacy of human factor VIII prepared by recombinant DNA techniques. Blood 1989: 74(Suppl.1): 55a.Google Scholar